At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed recurrent small cell lung cancer (SCLC) with measurable disease
- ✓Age 18 years or older
- ✓ECOG performance status 0-3
- ✓Prior chemotherapy for SCLC with resolved toxicities (≤grade 1)
- ✕Prior paclitaxel or interferon therapy
- ✕History of other cancer except non-metastatic/non-melanoma skin cancer, cervical carcinoma in situ, or cancer cured ≥5 years prior
- ✕Pregnant or nursing
- ✕Severe depression requiring medication
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Interferon Alpha (NSC# 377523) Plus 13-Cis-Retinoic Acid Modulation Of BCL-2 Plus Paclitaxel For Recurrent Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating interferon alpha, 13-cis-retinoic acid, and 1 other intervention for Lung Cancer. Completed, enrolled 37 participants across 73 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Giving interferon alfa and isotretinoin together with paclitaxel may reduce resistance to the drug and allow the tumor cells to be killed. PURPOSE: This phase II trial is studying how well giving interferon alfa and isotretinoin together with paclitaxel works in treating patients with recurrent small cell lung cancer.
Study Details
Timeline
Interventions
Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.